The microbiome and human cancer
Open accessThe DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index; 65 of the 179 sources its claims cite were checked for support.
Abstract
BACKGROUND: Historical accounts linking cancer and microbes date as early as four millennia ago. After establishment of the germ theory of infectious diseases, clinical research of microbial influences on cancer began in 1868, when William Busch reported spontaneous tumor regressions in patients with Streptococcus pyogenes infections. Over the next century, poor reproducibility, erroneous microbiological claims, and severe toxicity led many to discount the role of bacteria in carcinogenesis and cancer therapy. However, these studies provided the first crude demonstrations of cancer immunotherapy. Contemporaneously, the viral theory of cancer flourished, spurred by the 1911 discovery of Rous sarcoma virus, which transformed benign tissue into malignant tumors in chickens. The decades-long search to find viruses behind every human cancer ultimately failed, and many cancers have been linked to somatic mutations. Now the field is encountering intriguing claims of the importance of microbes, including bacteria and fungi, in cancer and cancer therapy. This Review critically evaluates this evidence in light of modern cancer biology and immunology, delineating roles for microbes in cancer by examining advances in proposed mechanisms, diagnostics, and modulation strategies. ADVANCES: Few microbes directly cause cancer, but many seem complicit in its growth, often acting through the host’s immune system; conversely, several have immunostimulatory properties. Mechanistic analyses of gut microbiota–immune system interactions reveal powerful effects on antitumor immunity by modulating primary and secondary lymphoid tissue activities. Many of these pathways invoke Toll-like receptor–initiated cytokine signaling, but microbial metabolic effects and antigenic mimicry with cancer cells are also important. In preclinical models, microbial metabolites also regulate phenotypes of tumor somatic mutations and modulate immune checkpoint inhibitor efficacy. Emerging evidence suggests that intratumoral bacteria exist and are active, with overlapping immunohistochemistry, immunofluorescence, electron microscopy, and sequencing data in ~10 cancer types. Preliminary studies further suggest that fungi and bacteriophages contribute to gastrointestinal cancers. However, the abundance of intratumoral microbial cells is low relative to cancer cells, and knowledge of their functional repertoire and potency remains limited. Further validation of their prevalence and impact is needed in diverse cohorts and therapeutic contexts. The immunomodulatory effects of host microbiota have reinvigorated efforts to change their composition as a form of immunotherapy. Despite extensive preclinical evidence, translation of microbiota modulation approaches into humans has not yet materialized into commercialized therapies. Synthetic biology approaches are also gaining traction, with engineered bacterial cancer therapies in preclinical and clinical trial settings. OUTLOOK: A better understanding of the roles of microbes in cancer provides an opportunity to improve each stage of the cancer care cycle, but major challenges remain. Concerted efforts to characterize cancer-associated microbiota among tumor, stool, and blood samples with gold-standard contamination controls would tremendously aid this progress. This would be analogous to The Cancer Genome Atlas’s role in characterizing the cancer somatic mutation landscape. Large-scale clinical trials are currently testing the efficacy of microbiota modulation approaches, ranging from dietary modifications to intratumorally injected, engineered bacteria. These bacterial cancer therapies, if safe and effective, could tremendously expand the cancer therapy armamentarium. Altogether, integrating the host-centric and microbial viewpoints of cancer may improve patient outcomes while providing a nuanced understanding of cancer-host-microbial evolution. Opportunities for microbes to affect cancer care.: Diagnosis: Cancer-specific, blood-borne microbial DNA may complement cell-free tumor DNA (ctDNA). Prognosis: Gut and intratumoral microbiota may stratify patient outcomes (NR, nonresponder; R, responder; TME, tumor microenvironment). Therapy: Intratumor injection of CD47 nanobody (CD47nb)–producing Escherichia coli may create systemic antitumor immunity by enhancing dendritic cell (DC) phagocytosis, lymph node (LN) antigen (Ag) presentation, and cytotoxic T lymphocyte (CTL) activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
28 Valid · 4 Not valid · 64 Not checked · 22 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“the number of microbes that inhabit the human body (roughly equal to the number of human cells)”
§ The microbiome and human cancer > Abstract > OUTLOOK:
What the sources say
- Supportedcites [27] Sender R, Fuchs S, Milo R, Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 14, e1002533 (2016). 27541692 PMC4991899 source
The Results section 'The Ratio of Bacteria to Human Cells in the Adult Body' states B/H = 1.3 (3.8·10^13 bacteria vs 3.0·10^13 human cells in the 70 kg reference man), explicitly described as 'about 1:1' replacing the 10:1 or 100:1 values. The Abstract likewise says the number of bacteria is 'of the same order as the number of human cells', and Table 3 shows the ratio stays near parity (1.3–2.3) across women, infants, elderly and obese segments. The paper also operationally equates 'microbial cells' with bacteria, since bacteria dominate the microbiome by 2–3 orders of magnitude. (LLM, conf=0.92)
- Disputedcites [28] Belkaid Y, Naik S, Compartmentalized and systemic control of tissue immunity by commensals. Nat. Immunol 14, 646– 653 (2013). 23778791 PMC3845005 sourceExperimental — accuracy not yet measured
Our copy states the opposite ratio: in 'Distinct anatomical sites have unique commensal communities' it says that with an estimated 100 trillion cells, commensals outnumber host cells by at least a factor of ten (and encode at least 100-fold more unique genes). No passage anywhere in the paper describes microbial and human cell numbers as roughly equal; searches for 'outnumber host cells / 100 trillion' and for 'number of microbial cells relative to human cells equal' returned only that sentence and unrelated topical passages. The parenthetical the citing sentence attributes to this source therefore contradicts what the source asserts. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [29] Fung TC, Olson CA, Hsiao EY, Interactions between the microbiota, immune and nervous systems in health and disease. Nat. Neurosci 20, 145– 155 (2017). 28092661 PMC6960010 sourceExperimental — accuracy not yet measured
The Abstract of Fung, Olson & Hsiao (2017) states that 'The human gastrointestinal tract is colonized by trillions of microorganisms collectively termed the gut microbiota', which supports the framing that the human body harbours an enormous microbial population, but locates it in the GI tract rather than the whole body. No passage in our copy compares microbial numbers to the number of human cells or states anything like a ~1:1 (or 10:1) ratio; searches for 'microbial cells outnumber human cells ratio tenfold', 'number of human cells', and microbiota diversity/abundance returned only the trillions-of-microorganisms statement and unrelated neuroimmune content. The quantitative equivalence attributed to this source is therefore not in our copy. (LLM, conf=0.72)
- Partly supportedcites [30] Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF, The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 359, 1366– 1370 (2018). 29567708 sourceExperimental — accuracy not yet measured
The only quantitative statement in our copy is in 'Early steps: A role for the microbiome in cancer': 'The human gut microbiome contains ~3 × 10^13 bacteria, most of which are commensals (5)' — a gut-restricted bacterial count, credited to reference 5. Nothing in our copy states a number of human cells or compares microbial counts to human cell counts, so the claim's central equivalence ('roughly equal to the number of human cells') and the whole-body scope are not supported by this source. Searches for 'number of human cells', 'microbial cells outnumber human cells', and '10^14' returned no such comparison; the paper does describe the host as a 'meta-organism' shaped by the gut microbiome, without any ratio to host cells. (LLM, conf=0.65)
- Not checked yetcites [31] Garrett WS, Cancer and the microbiota. Science. 348, 80– 86 (2015). 25838377 PMC5535753 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Increasing evidence suggests an important additional category of “complicit” microbes and microbial functions that promote carcinogenesis but are insufficient to cause cancer (18, 20, 25, 38, 44–47).”
§ The microbiome and human cancer > Overview of the cancer microbiome
What the sources say
- Supportedcites [18] Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, Ameh S, Sandel D, Liang XS, Mazzilli S, Whary MT, Meyerson M, Germain R, Blainey PC, Fox JG, Jacks T, Commensal Microbiota Promote Lung Cancer Development via γδ T Cells. Cell. 176, 998– 1013.e16 (2019). 30712876 PMC6691977 source
The Results (page unavailable) show that commensal microbiota increased tumor growth in mice whose lung tumors were initiated by Kras activation and p53 deletion. The Discussion (page unavailable) likewise describes early tumor development arising from those genetic changes, with local microbiota amplifying the response that promotes progression. This supports the cited paper as an example of microbes that promote carcinogenesis without being sufficient to initiate it. (LLM, conf=0.88)
- Partly supportedcites [20] Aykut B, Pushalkar S, Chen R, Li Q, Abengozar R, Kim JI, Shadaloey SA, Wu D, Preiss P, Verma N, Guo Y, Saxena A, Vardhan M, Diskin B, Wang W, Leinwand J, Kurz E, Kochen Rossi JA, Hundeyin M, Zambrinis C, Li X, Saxena D, Miller G, The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature. 574, 264– 267 (2019). 31578522 PMC6858566 sourceExperimental — accuracy not yet measured
The paper reports that fungal ablation protected against pancreatic tumor progression and that repopulation with Malassezia accelerated it (Abstract; page unavailable). Its experiments used mice with oncogenic Kras or implanted tumor cells, and it does not establish that the fungi are insufficient to cause cancer on their own. It also says whether fungal changes are a cause or consequence of oncogenesis is difficult to answer fully. (LLM, conf=0.86)
- Partly supportedcites [25] Tsay J-CJ, Wu BG, Sulaiman I, Gershner K, Schluger R, Li Y, Yie T-A, Meyn P, Olsen E, Perez L, Franca B, Carpenito J, Iizumi T, El-Ashmawy M, Badri M, Morton JT, Shen N, He L, Michaud G, Rafeq S, Bessich JL, Smith RL, Sauthoff H, Felner K, Pillai R, Zavitsanou A-M, Koralov SB, Mezzano V, Loomis CA, Moreira AL, Moore W, Tsirigos A, Heguy A, Rom WN, Sterman DH, Pass HI, Clemente JC, Li H, Bonneau R, Wong K-K, Papagiannakopoulos T, Segal LN, Lower airway dysbiosis affects lung cancer progression. Cancer Discov. (2020), doi: 10.1158/2159-8290.CD-20-0263. PMC7858243 33177060 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable in our copy) says that oral commensals such as Veillonella contribute to a pro-tumor immune environment and progression of existing non-small-cell lung cancer. The Methods describe introducing Veillonella after lung cancer was established in mice. This supports a role in progression, but the paper does not establish that these microbes or their functions are insufficient to cause cancer on their own. (LLM, conf=0.82)
- Supportedcites [38] Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, Wu X, DeStefano Shields CE, Hechenbleikner EM, Huso DL, Anders RA, Giardiello FM, Wick EC, Wang H, Wu S, Pardoll DM, Housseau F, Sears CL, Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science. 359, 592– 597 (2018). 29420293 PMC5881113 source
The paper reports that, in carcinogen-treated mice, either bacterial strain alone produced few to no tumors, whereas co-colonization produced pronounced tumor induction. It proposes complementary microbial mechanisms that enhance carcinogenesis, supporting the citing sentence’s point that microbes can contribute to cancer without being sufficient on their own. The supplied copy gives no page numbers. (LLM, conf=0.85)
- Supportedcites [44] Kadosh E, Snir-Alkalay I, Venkatachalam A, May S, Lasry A, Elyada E, Zinger A, Shaham M, Vaalani G, Mernberger M, Stiewe T, Pikarsky E, Oren M, Ben-Neriah Y, The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. Nature. 586, 133– 138 (2020). 32728212 PMC7116712 source
The Discussion (page unavailable) reports that the native gut microbiota or gallic acid converts mutant p53’s tumour-suppressive effect into oncogenic activity. In “Gallic acid mimics the microbiota effect” (page unavailable), gallic acid promotes dysplasia in mice with CKIα ablation and mutant p53, but has no effect on tumorigenesis in the tested mice with wild-type p53. This supports the cited paper as an example of a microbial function that promotes carcinogenesis in a susceptible context rather than causing it on its own. (LLM, conf=0.87)
- Partly supportedcites [45] Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Korangy F, Wang XW, Trinchieri G, Greten TF, Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 360 (2018), doi: 10.1126/science.aan5931. PMC6407885 29798856 sourceExperimental — accuracy not yet measured
The Results and ‘Alterations in the gut microbiome suppress liver tumors in multiple mouse models’ sections report that changing gut bacteria or bile-acid metabolism changes liver tumor growth, supporting a role for microbial functions in promoting cancer. The experiments used MYC-induced tumors or implanted tumor cells; they do not establish the broader claim that these microbes or functions are insufficient to cause cancer on their own. No page numbers are provided in our copy. (LLM, conf=0.84)
- Partly supportedcites [46] Le Noci V, Guglielmetti S, Arioli S, Camisaschi C, Bianchi F, Sommariva M, Storti C, Triulzi T, Castelli C, Balsari A, Tagliabue E, Sfondrini L, Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases. Cell Rep. 24, 3528– 3538 (2018). 30257213 sourceExperimental — accuracy not yet measured
The Discussion says lung commensal microbes can provide immunosuppressive signals, and the results show that changing the lung microbiota reduced metastasis implantation in mice given tumor cells. This supports a microbial role in facilitating cancer spread, but the paper does not establish a general category of “complicit” microbes that promote carcinogenesis, or explicitly assess whether those microbes can cause cancer on their own. The indexed passages provide section labels but no page numbers. (LLM, conf=0.83)
- Partly supportedcites [47] Meisel M, Hinterleitner R, Pacis A, Chen L, Earley ZM, Mayassi T, Pierre JF, Ernest JD, Galipeau HJ, Thuille N, Bouziat R, Buscarlet M, Ringus DL, Wang Y, Li Y, Dinh V, Kim SM, McDonald BD, Zurenski MA, Musch MW, Furtado GC, Lira SA, Baier G, Chang EB, Eren AM, Weber CR, Busque L, Godley LA, Verdú EF, Barreiro LB, Jabri B, Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature. 557, 580– 584 (2018). 29769727 PMC6238954 sourceExperimental — accuracy not yet measured
The Abstract reports that microbial signals drive pre-leukaemic myeloproliferation in Tet2-deficient mice, supporting a role for microbes in a precancerous condition that also requires host susceptibility. But the Abstract and Extended Data explicitly say whether those signals promote the additional mutations leading to leukaemia remains undetermined; the paper does not establish that they promote cancer itself. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Experimental evidence also implicates several microbes with virulence factors that amplify tumorigenesis via E-cadherin/Wnt/β-Catenin signaling, including FadA from Fusobacterium nucleatum and AvrA from several Salmonella strains (42, 43).”
§ The microbiome and human cancer > Overview of the cancer microbiome
What the sources say
- Partly supportedcites [42] Silva-García O, Valdez-Alarcón JJ, Baizabal-Aguirre VM, Wnt/β-Catenin Signaling as a Molecular Target by Pathogenic Bacteria. Front. Immunol 10, 2135 (2019). 31611869 PMC6776594 sourceExperimental — accuracy not yet measured
Our copy supports the AvrA/Salmonella half: the 'Salmonella enterica sv Typhimurium' section states that AvrA enhances β-catenin deubiquitination/stability and induces Wnt2, Wnt3, Wnt6, Wnt9a and Wnt11 (also tabulated in Table 1, Introduction), and concludes these effects 'may contribute to chronic disease and cell proliferation, leading to tumor development and cancer.' However, Fusobacterium nucleatum and FadA appear nowhere in our copy (searched: Fusobacterium, FadA, nucleatum); Table 1's inventory of bacteria with Wnt/β-catenin-affecting virulence factors does not include them, so that half of the claim is not attributable to this source. Additionally, the E-cadherin arm of the mechanism is described here for B. fragilis toxin, H. parasuis and H. pylori CagA, not for AvrA, and the tumorigenic outcome for AvrA is stated as a possibility ('may promote,' 'tempting to speculate') rather than the asserted amplification of tumorigenesis the citing sentence carries. (LLM, conf=0.82)
- Supportedcites [43] Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW, Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 14, 195– 206 (2013). 23954158 PMC3770529 source
Our copy of Rubinstein et al. (2013) states exactly the FadA/F. nucleatum half of the sentence: the INTRODUCTION summary reports that 'FadA modulates E-cadherin and activates β-catenin signaling, leading to increased expression of transcription factors, oncogenes, Wnt genes... as well as growth stimulation of CRC cells', the RESULTS (FadAc activates E-cadherin-mediated cellular signaling) show β-catenin nuclear translocation and CRT/TOPFlash activation dependent on E-cadherin and β-catenin, and the xenograft RESULTS (p. Fig. 6) show FadA increased HCT116 tumor growth by 20% via E-cadherin binding — i.e., a microbial virulence factor amplifying tumorigenesis through E-cadherin/Wnt/β-catenin. The DISCUSSION also frames the paper as reporting 'a mechanism by which Fn modulates E-cadherin/β-catenin signaling'. The AvrA/Salmonella clause of the citing sentence is carried by the companion citation in the (42, 43) pair; our copy contains no mention of Salmonella or AvrA (searched: AvrA, Salmonella, other bacterial virulence factors), so it neither supports nor contradicts that half — the only other microbe it credits with an E-cadherin/β-catenin mechanism is Bacteroides fragilis enterotoxin BFT (Wu et al., 1998; 2003). (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The TME comprises not only stromal, tumor, endothelial cells, and hematopoietic progenitor-derived immune components, but also a dense network of adrenergic nerve fibres that influence oncogenesis in brain and non-brain cancers (94–97).”
§ The microbiome and human cancer > Overview of the cancer microbiome > Mechanisms and interactions between the gut and tumor microbiome
What the sources say
- Partly supportedcites [94] Amit M, Takahashi H, Dragomir MP, Lindemann A, Gleber-Netto FO, Pickering CR, Anfossi S, Osman AA, Cai Y, Wang R, Knutsen E, Shimizu M, Ivan C, Rao X, Wang J, Silverman DA, Tam S, Zhao M, Caulin C, Zinger A, Tasciotti E, Dougherty PM, El-Naggar A, Calin GA, Myers JN, Loss of p53 drives neuron reprogramming in head and neck cancer. Nature. 578, 449– 454 (2020). 32051587 PMC9723538 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes adrenergic neo-nerves in the oral-cancer microenvironment and says neo-neural networks provide signals that coordinate cancer progression. The cited paper does not establish a dense adrenergic network in both brain and non-brain cancers, or document the sentence’s full list of microenvironmental cell types. (LLM, conf=0.87)
- Not checked yetcites [95] Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, Körber C, Kardorff M, Ratliff M, Xie R, Horstmann H, Messer M, Paik SP, Knabbe J, Sahm F, Kurz FT, Acikgöz AA, Herrmannsdörfer F, Agarwal A, Bergles DE, Chalmers A, Miletic H, Turcan S, Mawrin C, Hänggi D, Liu H-K, Wick W, Winkler F, Kuner T, Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 573, 532– 538 (2019). 31534219 source
- Partly supportedcites [96] Zeng Q, Michael IP, Zhang P, Saghafinia S, Knott G, Jiao W, McCabe BD, Galván JA, Robinson HPC, Zlobec I, Ciriello G, Hanahan D, Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature. 573, 526– 531 (2019). 31534217 PMC6837873 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) supports a narrower point: interactions with neurons promote growth of breast-cancer metastases in the brain. The Introduction (page unavailable) also reports earlier findings on NMDAR signalling in pancreatic cancers. Neither passage describes a dense network of adrenergic nerve fibres or establishes the stated list of tumour-microenvironment components; the Discussion treats comparable interactions with peripheral nerves as a question for future study. (LLM, conf=0.84)
- Partly supportedcites [97] Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M, Tam LT, Espenel C, Ponnuswami A, Ni L, Woo PJ, Taylor KR, Agarwal A, Regev A, Brang D, Vogel H, Hervey-Jumper S, Bergles DE, Suvà ML, Malenka RC, Monje M, Electrical and synaptic integration of glioma into neural circuits. Nature. 573, 539– 545 (2019). 31534222 PMC7038898 sourceExperimental — accuracy not yet measured
The Discussion (page not provided) identifies neurons as part of the glioma microenvironment and describes neuronal signaling that drives glioma growth. The paper does not establish a dense network of adrenergic fibres, the listed stromal and immune-cell composition, or effects on non-brain cancers. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“intratumor microbes have been reported to have cancer-specific effects on (i) gastrointestinal and urinary tract mutagenesis via secreted genotoxins, most notably pks+ E. coli-derived colibactin and B. fragilis-derived toxin (22, 37, 38, 40, 41)”
§ The microbiome and human cancer > Overview of the cancer microbiome > Mechanisms and interactions between the gut and tumor microbiome
What the sources say
- Not checked yetcites [22] Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, van Hoeck A, Wood HM, Nomburg J, Gurjao C, Manders F, Dalmasso G, Stege PB, Paganelli FL, Geurts MH, Beumer J, Mizutani T, Miao Y, van der Linden R, van der Elst S, Genomics England Research Consortium, Garcia KC, Top J, Willems RJL, Giannakis M, Bonnet R, Quirke P, Meyerson M, Cuppen E, van Boxtel R, Clevers H, Mutational signature in colorectal cancer caused by genotoxic pks E. coli. Nature. 580, 269– 273 (2020). 32106218 PMC8142898 source
- Partly supportedcites [37] Wilson MR, Jiang Y, Villalta PW, Stornetta A, Boudreau PD, Carrá A, Brennan CA, Chun E, Ngo L, Samson LD, Engelward BP, Garrett WS, Balbo S, Balskus EP, The human gut bacterial genotoxin colibactin alkylates DNA. Science. 363 (2019), doi: 10.1126/science.aar7785. PMC6407708 30765538 sourceExperimental — accuracy not yet measured
The DNA-adduct experiments report colibactin-associated DNA damage in colonic epithelial cells and in mice colonized with pks+ E. coli. The Conclusions say resulting mutations may contribute to cancer, but do not establish cancer-specific mutagenesis. This paper does not support the sentence’s urinary-tract or B. fragilis-toxin components. (LLM, conf=0.87)
- Partly supportedcites [38] Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, Wu X, DeStefano Shields CE, Hechenbleikner EM, Huso DL, Anders RA, Giardiello FM, Wick EC, Wang H, Wu S, Pardoll DM, Housseau F, Sears CL, Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science. 359, 592– 597 (2018). 29420293 PMC5881113 sourceExperimental — accuracy not yet measured
The passage labeled Abstract (page not provided) identifies colibactin and B. fragilis toxin as secreted oncotoxins and reports increased colonic epithelial DNA damage and tumorigenesis when mice were cocolonized with the two bacteria. The paper concerns colonic mucosal biofilms in patients with familial adenomatous polyposis and colon-tumor models; it does not establish urinary-tract mutagenesis or effects of intratumor microbes across cancers. It attributes the observed DNA damage specifically to colibactin, rather than showing that B. fragilis toxin itself causes mutagenesis. (LLM, conf=0.87)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
59 more claims · 12 with their cited sources checked
Create a free account to see all 118 claims and to verify the 114 references still open.
- It may state two separate claims as one. 52
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The gut microbiome is increasingly recognized as a modifiable risk factor in multiple cancer types, including colorectal, gastric, and pancreatic cancers [12,41–43]”
From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recognition of the pivotal role of the microbiome in cancer initiation, progression, and treatment response has opened new avenues for therapeutic intervention [7–12]”
From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [12]
In the citing paper
“Parallel studies have demonstrated that the composition of the intestinal microbiota exhibits numerous disease-relevant changes in cancer patients.”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The microbiome and human cancer > Overview of the cancer microbiome
“just 11 are labeled human carcinogens, or “oncomicrobes,” by the International Association for Cancer Registries (IACR) (36).”
§ The microbiome and human cancer > References
“36. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Biological agents. Volume 100 B. A review of human carcinogens.”
Citations
Cites
1 retracted
RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach
Poore, G. D., Kopylova, E., Zhu, Q., Carpenter, C., Fraraccio, S., Wandro, S., Kosciolek, T., Janssen, S., Metcalf, J., Song, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2095-1 · Cited by 989
Self-citationRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
Self-citationThe Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationRevised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425 · cited 1×
“1 to 1% are archaea and eukarya (including fungi) (27, 48).”
BackgroundGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1×
“Moreover, observations in humans and mice of gut microbes that stratify therapy response, particularly immunotherapy (16, 17, 21, 26), have not uncommonly shown varying taxonomic differences that persist despite uniform bioinformatic reanalyses, although there is greater concordance when examining functional profiles…”
BackgroundSelf-citationGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · cited 1×
“Molecular mimicry between cancer and microbial antigens has also been hinted (82) and recently studied in depth (83).”
BackgroundCommensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“thatmediates Toll-like receptor 4 (TLR4)– and IL-12–dependent TH1 responses and therapeutic efficacy (70); (iii) inhibition of programmed cell death protein 1 and/or its ligand [PD-(L)1] leads to T cell priming against melanoma and is more effective when hosts harbor Bifidobacteria species in their microbiome (21, 71)…”
BackgroundDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“FMT treats Clostridium difficile (now Clostridioides difficile) colitis effectively (140), with some efficacy in the treatment of immunotherapyassociated colitis (141).”
BackgroundDavis, N. M., Proctor, D. M., Holmes, S. P., Relman, D. A., & Callahan, B. J. (2018) · Microbiome · doi:10.1186/s40168-018-0605-2 · Cited by 3,493
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“thatmediates Toll-like receptor 4 (TLR4)– and IL-12–dependent TH1 responses and therapeutic efficacy (70); (iii) inhibition of programmed cell death protein 1 and/or its ligand [PD-(L)1] leads to T cell priming against melanoma and is more effective when hosts harbor Bifidobacteria species in their microbiome (21, 71)…”
BackgroundSelf-citationThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 2×
“thatmediates Toll-like receptor 4 (TLR4)– and IL-12–dependent TH1 responses and therapeutic efficacy (70); (iii) inhibition of programmed cell death protein 1 and/or its ligand [PD-(L)1] leads to T cell priming against melanoma and is more effective when hosts harbor Bifidobacteria species in their microbiome (21, 71)…”
BackgroundPan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
Rubinstein, M. R., Wang, X., Liu, W., Hao, Y., Cai, G., & Han, Y. W. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.07.012 · Cited by 2,476 · cited 1×
“Experimental evidence also implicates several microbes with virulence factors that amplify tumorigenesis through E-cadherin– Wnt–b-catenin signaling, including FadA from Fusobacterium nucleatum and AvrA from several Salmonella strains (42, 43).”
BackgroundThe human tumor microbiome is composed of tumor type–specific intracellular bacteria
Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464 · cited 8×
“used quantitative polymerase chain reaction (qPCR) of 16S ribosomal RNA (rRNA) to estimate the number of bacteria relative to 40 ng of DNA inmelanoma, lung, ovarian, glioblastoma, pancreatic, bone, and breast cancer tissue sections (12).”
BackgroundMethodInfluentialSelf-citationSingh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H., Thangaraju, M., Prasad, P. D., Manicassamy, S., Munn, D. H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.007 · Cited by 2,368 · cited 1×
“Secretory components of gut microbiota can be important: For example, outer membrane vesicles (OMVs) can reprogram the TME toward a pro-TH1 pattern (CXCL10, IFN-g) (88), or metabolites, including butyrate and niacin, can mediate Gpr109a-dependent induction of IL-18 in colonic epithelium and suppress colitis and colon…”
BackgroundComprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256 · cited 1×
“For example, a blood-derived TP53 mutation can indicate host cancer status but implicates >25 cancer types (115); conversely, Streptococcus gallolyticus (formerly S.”
BackgroundCommensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.008 · Cited by 2,198
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Self-citationFusobacterium nucleatum infection is prevalent in human colorectal carcinoma
Castellarin, M., Warren, R. L., Freeman, J. D., Dreolini, L., Krzywinski, M., Strauss, J., Barnes, R., Watson, P., Allen-Vercoe, E., Moore, R. A., et al. (2012) · Genome Research · doi:10.1101/gr.126516.111 · Cited by 2,043
Interactions between the microbiota, immune and nervous systems in health and disease
Fung, T. C., Olson, C. A., & Hsiao, E. Y. (2017) · Nature Neuroscience · doi:10.1038/nn.4476 · Cited by 1,900
The microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846
Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., et al. (2017) · Science · doi:10.1126/science.aah5043 · Cited by 1,817 · cited 2×
“fragilis–derived toxin (22, 37, 38, 40, 41); (ii) CagA-mediated or IL-17– producing gd T cell–mediated inflammation in stomach and lung cancers, respectively (18, 103); (iii) chemoresistance through direct microbial metabolism (cytidine deaminase degradation of gemcitabine) in pancreatic cancer or indirect amplificati…”
BackgroundSelf-citationFecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781 · cited 1×
“Completion of microbiotamodulation trials are additionally crucial for guiding clinical applications and increasing the cancer therapy armamentarium (142), with new evidence demonstrating that modulation of the gut microbiota using FMT in immunotherapy-refractory melanoma patients is associated with clinical responses…”
BackgroundFecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
Self-citationTumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes
Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., Quesada, P., Sahin, I., Chandra, V., San Lucas, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.008 · Cited by 1,577
Self-citationAnalysis of Fusobacterium persistence and antibiotic response in colorectal cancer
Bullman, S., Pedamallu, C. S., Sicinska, E., Clancy, T. E., Zhang, X., Cai, D., Neuberg, D., Huang, K., Guevara, F., Nelson, T., et al. (2017) · Science · doi:10.1126/science.aal5240 · Cited by 1,574 · cited 4×
“hematogenous spread (117, 172, 173) or colonized micrometastases (19) may”
BackgroundInfluentialGut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508
Yachida, S., Mizutani, S., Shiroma, H., Shiba, S., Nakajima, T., Sakamoto, T., Watanabe, H., Masuda, K., Nishimoto, Y., Kubo, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0458-7 · Cited by 1,429
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407 · cited 1×
“Anti–CTLA-4–induced gut barrier dysfunction was also critical for systemic translocation of Bifidobacterium-derived inosine, in turn promoting TH1 activation and antitumor immunity by agonizing T cell–specific adenosine 2A receptor (A2AR) signaling in the context of DC costimulation (93).”
BackgroundGarrett, W. S. (2015) · Science · doi:10.1126/science.aaa4972 · Cited by 1,404 · cited 2×
“Nearly all microbial-based cancer diagnostics are sequencing-based and have focused on tumors within the aerodigestive tract (31), such as colorectal (118–121), pancreatic (122, 123), and lung cancer (124–126).”
BackgroundPushalkar, S., Hundeyin, M., Daley, D., Zambirinis, C. P., Kurz, E., Mishra, A., Mohan, N., Aykut, B., Usyk, M., Torres, L. E., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1134 · Cited by 1,400
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392 · cited 1×
“Although most proposed cancer-microbe relationships focus on gut microbiota (30, 32, 33), recent studies also contentiously suggest the existence, metabolic activity, and functional importance of intratumoral microbiota using a combination of imaging, sequencing, and cultivation techniques and genetically engineered a…”
BackgroundSelf-citationWirbel, J., Pyl, P. T., Kartal, E., Zych, K., Kashani, A., Milanese, A., Fleck, J. S., Voigt, A. Y., Palleja, A., Ponnudurai, R., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0406-6 · Cited by 1,373
Electrical and synaptic integration of glioma into neural circuits
Venkatesh, H. S., Morishita, W., Geraghty, A. C., Silverbush, D., Gillespie, S. M., Arzt, M., Tam, L. T., Espenel, C., Ponnuswami, A., Ni, L., et al. (2019) · Nature · doi:10.1038/s41586-019-1563-y · Cited by 1,366
A new genomic blueprint of the human gut microbiota
Almeida, A., Mitchell, A. L., Boland, M., Forster, S. C., Gloor, G. B., Tarkowska, A., Lawley, T. D., & Finn, R. D. (2019) · Nature · doi:10.1038/s41586-019-0965-1 · Cited by 1,314
Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli
Pleguezuelos-Manzano, C., Puschhof, J., Rosendahl Huber, A., van Hoeck, A., Wood, H. M., Nomburg, J., Gurjao, C., Manders, F., Dalmasso, G., Stege, P. B., et al. (2020) · Nature · doi:10.1038/s41586-020-2080-8 · Cited by 1,208 · cited 2×
“fragilis–derived toxin (22, 37, 38, 40, 41); (ii) CagA-mediated or IL-17– producing gd T cell–mediated inflammation in stomach and lung cancers, respectively (18, 103); (iii) chemoresistance through direct microbial metabolism (cytidine deaminase degradation of gemcitabine) in pancreatic cancer or indirect amplificati…”
BackgroundThe microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200 · cited 1×
“Although most proposed cancer-microbe relationships focus on gut microbiota (30, 32, 33), recent studies also contentiously suggest the existence, metabolic activity, and functional importance of intratumoral microbiota using a combination of imaging, sequencing, and cultivation techniques and genetically engineered a…”
BackgroundSelf-citationGlutamatergic synaptic input to glioma cells drives brain tumour progression
Venkataramani, V., Tanev, D. I., Strahle, C., Studier-Fischer, A., Fankhauser, L., Kessler, T., Körber, C., Kardorff, M., Ratliff, M., Xie, R., et al. (2019) · Nature · doi:10.1038/s41586-019-1564-x · Cited by 1,197
Scaling laws predict global microbial diversity
Locey, K. J., & Lennon, J. T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521291113 · Cited by 1,184
Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity
Clarke, T. B., Davis, K. M., Lysenko, E. S., Zhou, A. Y., Yu, Y., & Weiser, J. N. (2010) · Nature Medicine · doi:10.1038/nm.2087 · Cited by 1,154 · cited 1×
“Microbiota-derived compounds can protect against irradiation-induced hematopoietic injury (60–62) through production of propionate and tryptophan metabolites (63) or by releasing microorganism-associated molecular patterns (MAMPs) known to maintain BM-derivedmyeloid cells and neutrophil function (64, 65).”
BackgroundContamination in Low Microbial Biomass Microbiome Studies: Issues and Recommendations
Eisenhofer, R., Minich, J. J., Marotz, C., Cooper, A., Knight, R., & Weyrich, L. S. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.11.003 · Cited by 1,146
Self-citationA defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Tanoue, T., Morita, S., Plichta, D. R., Skelly, A. N., Suda, W., Sugiura, Y., Narushima, S., Vlamakis, H., Motoo, I., Sugita, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0878-z · Cited by 1,145 · cited 1×
“For example, Tanoue and colleagues identified an 11-bacteria cocktail that increased tumor antigen–specific CD8 IFN-g T cells in the context of immune checkpoint blockade that were not cross-reactive with microbial antigens and did not originate from the colon (84).”
BackgroundPatients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria
Dejea, C. M., Fathi, P., Craig, J. M., Boleij, A., Taddese, R., Geis, A. L., Wu, X., DeStefano Shields, C. E., Hechenbleikner, E. M., Huso, D. L., et al. (2018) · Science · doi:10.1126/science.aah3648 · Cited by 1,105 · cited 1×
“fragilis–derived toxin (22, 37, 38, 40, 41); (ii) CagA-mediated or IL-17– producing gd T cell–mediated inflammation in stomach and lung cancers, respectively (18, 103); (iii) chemoresistance through direct microbial metabolism (cytidine deaminase degradation of gemcitabine) in pancreatic cancer or indirect amplificati…”
BackgroundMultiplex digital spatial profiling of proteins and RNA in fixed tissue
Merritt, C. R., Ong, G. T., Church, S. E., Barker, K., Danaher, P., Geiss, G., Hoang, M., Jung, J., Liang, Y., McKay-Fleisch, J., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0472-9 · Cited by 1,072
A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS
Rous, P. (1911) · Journal of Experimental Medicine · doi:10.1084/jem.13.4.397 · Cited by 1,051
Thomas, A. M., Manghi, P., Asnicar, F., Pasolli, E., Armanini, F., Zolfo, M., Beghini, F., Manara, S., Karcher, N., Pozzi, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0405-7 · Cited by 1,030
Commensal Microbiota Promote Lung Cancer Development via γδ T Cells
Jin, C., Lagoudas, G. K., Zhao, C., Bullman, S., Bhutkar, A., Hu, B., Ameh, S., Sandel, D., Liang, X. S., Mazzilli, S., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.040 · Cited by 964
Phage diversity, genomics and phylogeny
Dion, M. B., Oechslin, F., & Moineau, S. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0311-5 · Cited by 960
The evolution of the host microbiome as an ecosystem on a leash
Foster, K. R., Schluter, J., Coyte, K. Z., & Rakoff-Nahoum, S. (2017) · Nature · doi:10.1038/nature23292 · Cited by 935
Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908 · cited 1×
“However, increasing clinical evidence suggests that systemic antibiotics abolish immune checkpoint blockade efficacy and decrease patient survival (133, 136, 137).”
BackgroundSelf-citationEngineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905 · cited 2×
“Though historically contentious, BCT is regaining attention through synthetic biology techniques that programmatically limit systemic toxicities while enhancing regional antitumor immunity (105, 106).”
BackgroundDaillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.009 · Cited by 897 · cited 1×
“Anticancer therapies have demonstrated strong links between distinct commensals and protective antitumor T cell responses: (i) Cyclophosphamide enables Enterococcus hirae to translocate and stimulate pathogenic helper T cell 17 (TH17) responses and IFN-producing CD8 T cell effectors that check tumor growth in sarcoma…”
BackgroundSelf-citationAbed, J., Emgård, J. E. M., Zamir, G., Faroja, M., Almogy, G., Grenov, A., Sol, A., Naor, R., Pikarsky, E., Atlan, K. A., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.07.006 · Cited by 888
The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL
Aykut, B., Pushalkar, S., Chen, R., Li, Q., Abengozar, R., Kim, J. I., Shadaloey, S. A., Wu, D., Preiss, P., Verma, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1608-2 · Cited by 883
Culturing the human microbiota and culturomics
Lagier, J.-C., Dubourg, G., Million, M., Cadoret, F., Bilen, M., Fenollar, F., Levasseur, A., Rolain, J.-M., Fournier, P.-E., & Raoult, D. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0041-0 · Cited by 872
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821 · cited 2×
“Though historically contentious, BCT is regaining attention through synthetic biology techniques that programmatically limit systemic toxicities while enhancing regional antitumor immunity (105, 106).”
BackgroundTumour-associated and non-tumour-associated microbiota in colorectal cancer
Flemer, B., Lynch, D. B., Brown, J. M. R., Jeffery, I. B., Ryan, F. J., Claesson, M. J., O'Riordain, M., Shanahan, F., & O'Toole, P. W. (2017) · Gut · doi:10.1136/gutjnl-2015-309595 · Cited by 804
Homeostasis and Inflammation in the Intestine
Garrett, W. S., Gordon, J. I., & Glimcher, L. H. (2010) · Cell · doi:10.1016/j.cell.2010.01.023 · Cited by 784
Synchronized cycles of bacterial lysis for in vivo delivery
Din, M. O., Danino, T., Prindle, A., Skalak, M., Selimkhanov, J., Allen, K., Julio, E., Atolia, E., Tsimring, L. S., Bhatia, S. N., et al. (2016) · Nature · doi:10.1038/nature18930 · Cited by 784
Self-citationThe microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aar6918 · Cited by 777
Self-citationMicrobiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
Peled, J. U., Gomes, A. L. C., Devlin, S. M., Littmann, E. R., Taur, Y., Sung, A. D., Weber, D., Hashimoto, D., Slingerland, A. E., Slingerland, J. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1900623 · Cited by 765 · cited 4×
“The effects of gut microbiota on primary lymphoid organs After allogeneic hematopoietic stem cell transplantation (HSCT), robust immune reconstitution governs both relapse and transplant-related patientmortality (56, 57).”
BackgroundInfluentialFecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740 · cited 1×
“FMT treats Clostridium difficile (now Clostridioides difficile) colitis effectively (140), with some efficacy in the treatment of immunotherapyassociated colitis (141).”
BackgroundSelf-citationProgrammable bacteria induce durable tumor regression and systemic antitumor immunity
Chowdhury, S., Castro, S., Coker, C., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2019) · Nature Medicine · doi:10.1038/s41591-019-0498-z · Cited by 724 · cited 2×
“the cyclical delivery of therapeutics (155, 156, 175).”
BackgroundMethodThe microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., & Turnbaugh, P. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.17 · Cited by 717
Parhi, L., Alon-Maimon, T., Sol, A., Nejman, D., Shhadeh, A., Fainsod-Levi, T., Yajuk, O., Isaacson, B., Abed, J., Maalouf, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16967-2 · Cited by 716
Self-citationFrankel, A. E., Coughlin, L. A., Kim, J., Froehlich, T. W., Xie, Y., Frenkel, E. P., & Koh, A. Y. (2017) · Neoplasia · doi:10.1016/j.neo.2017.08.004 · Cited by 709
An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models
Burdelya, L. G., Krivokrysenko, V. I., Tallant, T. C., Strom, E., Gleiberman, A. S., Gupta, D., Kurnasov, O. V., Fort, F. L., Osterman, A. L., DiDonato, J. A., et al. (2008) · Science · doi:10.1126/science.1154986 · Cited by 705
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
Fusobacterium nucleatum and T Cells in Colorectal Carcinoma
Mima, K., Sukawa, Y., Nishihara, R., Qian, Z. R., Yamauchi, M., Inamura, K., Kim, S. A., Masuda, A., Nowak, J. A., Nosho, K., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1377 · Cited by 669
Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer
Farrell, J. J., Zhang, L., Zhou, H., Chia, D., Elashoff, D., Akin, D., Paster, B. J., Joshipura, K., & Wong, D. T. W. (2012) · Gut · doi:10.1136/gutjnl-2011-300784 · Cited by 662
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647 · cited 1×
“the cyclical delivery of therapeutics (155, 156, 175).”
BackgroundGut Microbiota Promote Hematopoiesis to Control Bacterial Infection
Khosravi, A., Yáñez, A., Price, J. G., Chow, A., Merad, M., Goodridge, H. S., & Mazmanian, S. K. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.006 · Cited by 644
The Human Gut Bacterial Genotoxin Colibactin Alkylates DNA
Wilson, M. R., Jiang, Y., Villalta, P. W., Stornetta, A., Boudreau, P. D., Carrá, A., Brennan, C. A., Chun, E., Ngo, L., Samson, L. D., et al. (2019) · Science · doi:10.1126/science.aar7785 · Cited by 635
Wang, L., Tang, L., Feng, Y., Zhao, S., Han, M., Zhang, C., Yuan, G., Zhu, J., Cao, S., Wu, Q., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-320105 · Cited by 630 · cited 1×
“muciniphila or its pili-like TLR2 agonist blunted azoxymethaneinduced colitis and colon carcinogenesis by inducing TNFa-producing cytotoxic T lymphocytes in mesenteric lymph nodes (mLNs) that eventually reached the colonic mucosa (91).”
BackgroundPinato, D. J., Howlett, S., Ottaviani, D., Urus, H., Patel, A., Mineo, T., Brock, C., Power, D., Hatcher, O., Falconer, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2785 · Cited by 626 · cited 2×
“However, increasing clinical evidence suggests that systemic antibiotics abolish immune checkpoint blockade efficacy and decrease patient survival (133, 136, 137).”
BackgroundThe Microbiota of Breast Tissue and Its Association with Breast Cancer
Urbaniak, C., Gloor, G. B., Brackstone, M., Scott, L., Tangney, M., & Reid, G. (2016) · Applied and Environmental Microbiology · doi:10.1128/aem.01235-16 · Cited by 625
Qiita: rapid, web-enabled microbiome meta-analysis
Gonzalez, A., Navas-Molina, J. A., Kosciolek, T., McDonald, D., Vázquez-Baeza, Y., Ackermann, G., DeReus, J., Janssen, S., Swafford, A. D., Orchanian, S. B., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0141-9 · Cited by 624
Self-citationBacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response
Kim, O. Y., Park, H. T., Dinh, N. T. H., Choi, S. J., Lee, J., Kim, J. H., Lee, S.-W., & Gho, Y. S. (2017) · Nature Communications · doi:10.1038/s41467-017-00729-8 · Cited by 616
The gut microbiota is associated with immune cell dynamics in humans
Schluter, J., Peled, J. U., Taylor, B. P., Markey, K. A., Smith, M., Taur, Y., Niehus, R., Staffas, A., Dai, A., Fontana, E., et al. (2020) · Nature · doi:10.1038/s41586-020-2971-8 · Cited by 601
Erdag, G., Schaefer, J. T., Smolkin, M. E., Deacon, D. H., Shea, S. M., Dengel, L. T., Patterson, J. W., & Slingluff, C. L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3218 · Cited by 590
Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9537 · Cited by 588 · cited 1×
“5B), with intratumoral or intravenous injection often leading to ~10,000-fold accumulation in tumors relative to matched liver, spleen, and lung tissues (152, 153).”
BackgroundThe Microbiome Quality Control Project Consortium, Sinha, R., Abu-Ali, G., Vogtmann, E., Fodor, A. A., Ren, B., Amir, A., Schwager, E., Crabtree, J., Ma, S., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3981 · Cited by 587 · cited 1×
“data and guide the selection of “gold-standard” pipelines, analogous to theMicrobiomeQuality Control consortium’s analysis of fecal amplicon sequencing among 15 laboratories and nine bioinformatic protocols (163).”
MethodSelf-citationPaulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586
Synaptic proximity enables NMDAR signalling to promote brain metastasis
Zeng, Q., Michael, I. P., Zhang, P., Saghafinia, S., Knott, G., Jiao, W., McCabe, B. D., Galván, J. A., Robinson, H. P. C., Zlobec, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1576-6 · Cited by 574
(2012) · PubMed Central · Cited by 570
Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis
Ansaldo, E., Slayden, L. C., Ching, K. L., Koch, M. A., Wolf, N. K., Plichta, D. R., Brown, E. M., Graham, D. B., Xavier, R. J., Moon, J. J., et al. (2019) · Science · doi:10.1126/science.aaw7479 · Cited by 566 · cited 2×
“Apart from providing DC adjuvants, the gut microbiota represent an antigen source that can elicit commensal-specific T cell responses systemically (55, 78).”
BackgroundMulti-omics analyses of radiation survivors identify radioprotective microbes and metabolites
Guo, H., Chou, W.-C., Lai, Y., Liang, K., Tam, J. W., Brickey, W. J., Chen, L., Montgomery, N. D., Li, X., Bohannon, L. M., et al. (2020) · Science · doi:10.1126/science.aay9097 · Cited by 561 · cited 3×
“Microbiota-derived compounds can protect against irradiation-induced hematopoietic injury (60–62) through production of propionate and tryptophan metabolites (63) or by releasing microorganism-associated molecular patterns (MAMPs) known to maintain BM-derivedmyeloid cells and neutrophil function (64, 65).”
BackgroundMicrobiota of Human Breast Tissue
Urbaniak, C., Cummins, J., Brackstone, M., Macklaim, J. M., Gloor, G. B., Baban, C. K., Scott, L., O'Hanlon, D. M., Burton, J. P., Francis, K. P., et al. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.00242-14 · Cited by 552
Association of Streptococcus bovis with Carcinoma of the Colon
Klein, R. S., Recco, R. A., Catalano, M. T., Edberg, S. C., Casey, J. I., & Steigbigel, N. H. (1977) · New England Journal of Medicine · doi:10.1056/nejm197710132971503 · Cited by 532
Developing a new class of engineered live bacterial therapeutics to treat human diseases
Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020) · Nature Communications · doi:10.1038/s41467-020-15508-1 · Cited by 523 · cited 1×
“, NCT04167137), they have yet to be commercially surmounted (151).”
BackgroundSystemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
Coutzac, C., Jouniaux, J.-M., Paci, A., Schmidt, J., Mallardo, D., Seck, A., Asvatourian, V., Cassard, L., Saulnier, P., Lacroix, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16079-x · Cited by 513 · cited 3×
“Moreover, increased ex vivo outgrowth of A.muciniphila by prebiotic mucin decreased growth kinetics of aggressive melanoma inagutmicrobiota– andT cell–dependent manner, reducing serum levels of proinflammatory and immunosuppressive IL-6, IL-1a, IL-10, IL-17A, and IL-23 cytokines (87); notably, prebiotic inulin operate…”
BackgroundLoss of p53 drives neuron reprogramming in head and neck cancer
Amit, M., Takahashi, H., Dragomir, M. P., Lindemann, A., Gleber-Netto, F. O., Pickering, C. R., Anfossi, S., Osman, A. A., Cai, Y., Wang, R., et al. (2020) · Nature · doi:10.1038/s41586-020-1996-3 · Cited by 483
Microbiome and Anticancer Immunosurveillance
Zitvogel, L., Ayyoub, M., Routy, B., & Kroemer, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.001 · Cited by 478
Self-citationInteraction between the microbiome and TP53 in human lung cancer
Greathouse, K. L., White, J. R., Vargas, A. J., Bliskovsky, V. V., Beck, J. A., von Muhlinen, N., Polley, E. C., Bowman, E. D., Khan, M. A., Robles, A. I., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1501-6 · Cited by 446
Host–microbiota maladaptation in colorectal cancer
Janney, A., Powrie, F., & Mann, E. H. (2020) · Nature · doi:10.1038/s41586-020-2729-3 · Cited by 445
Dr William Coley and tumour regression: a place in history or in the future
Hoption Cann, S. A., van Netten, J. P., & van Netten, C. (2003) · Postgraduate Medical Journal · doi:10.1093/postgradmedj/79.938.672 · Cited by 433
Meta-analyses of studies of the human microbiota
Lozupone, C. A., Stombaugh, J., Gonzalez, A., Ackermann, G., Wendel, D., Vázquez-Baeza, Y., Jansson, J. K., Gordon, J. I., & Knight, R. (2013) · Genome Research · doi:10.1101/gr.151803.112 · Cited by 424
Self-citationHe, Z., Gharaibeh, R. Z., Newsome, R. C., Pope, J. L., Dougherty, M. W., Tomkovich, S., Pons, B., Mirey, G., Vignard, J., Hendrixson, D. R., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317200 · Cited by 409
Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling
Shi, Y., Zheng, W., Yang, K., Harris, K. G., Ni, K., Xue, L., Lin, W., Chang, E. B., Weichselbaum, R. R., & Fu, Y.-X. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20192282 · Cited by 409
Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host
Meisel, M., Hinterleitner, R., Pacis, A., Chen, L., Earley, Z. M., Mayassi, T., Pierre, J. F., Ernest, J. D., Galipeau, H. J., Thuille, N., et al. (2018) · Nature · doi:10.1038/s41586-018-0125-z · Cited by 406 · cited 2×
“Spontaneous gut bacterial translocation in Tet2 mice also drove preleukemic myeloproliferation (PMP), which leads to leukemia if unchecked, in an IL-6–dependent manner (47).”
BackgroundIntratumoral injection of Clostridium novyi -NT spores induces antitumor responses
Roberts, N. J., Zhang, L., Janku, F., Collins, A., Bai, R.-Y., Staedtke, V., Rusk, A. W., Tung, D., Miller, M., Roix, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008982 · Cited by 400 · cited 1×
“5B), with intratumoral or intravenous injection often leading to ~10,000-fold accumulation in tumors relative to matched liver, spleen, and lung tissues (152, 153).”
BackgroundNomura, M., Nagatomo, R., Doi, K., Shimizu, J., Baba, K., Saito, T., Matsumoto, S., Inoue, K., & Muto, M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.2895 · Cited by 396 · cited 1×
“High blood butyrate and propionate levels were also associated with resistance to CTLA-4 blockade in mice and melanoma patients, with concomitantly increased regulatory T cell (Treg) proportions, reduced DC and effector T cell activation, and lower responses to IL-2 (85), although they were also found to be associated…”
BackgroundCross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., et al. (2020) · Science · doi:10.1126/science.aax0701 · Cited by 396 · cited 4×
“may share epitopes with microbes through molecular mimicry (73, 83).”
BackgroundInfluentialSelf-citationThe human microbiome in evolution
Davenport, E. R., Sanders, J. G., Song, S. J., Amato, K. R., Clark, A. G., & Knight, R. (2017) · BMC Biology · doi:10.1186/s12915-017-0454-7 · Cited by 393
Self-citationCompartmentalized and systemic control of tissue immunity by commensals
Belkaid, Y., & Naik, S. (2013) · Nature Immunology · doi:10.1038/ni.2604 · Cited by 382
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
Kadosh, E., Snir-Alkalay, I., Venkatachalam, A., May, S., Lasry, A., Elyada, E., Zinger, A., Shaham, M., Vaalani, G., Mernberger, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2541-0 · Cited by 378 · cited 1×
“One example is that common p53 mutations are only carcinogenic in the presence of microbially produced gallic acid and are protective otherwise in the gut, both in vivo and in organoids, suggesting a microbiomefunctional genomic interaction (44).”
BackgroundModulating the microbiome to improve therapeutic response in cancer
McQuade, J. L., Daniel, C. R., Helmink, B. A., & Wargo, J. A. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30952-5 · Cited by 376
Self-citationDiscovery and validation of potential bacterial biomarkers for lung cancer.
Yan, X., Yang, M., Liu, J., Gao, R., Hu, J., Li, J., Zhang, L., Shi, Y., Guo, H., Cheng, J., et al. (2015) · Europe PMC (PubMed Central) · Cited by 366
The Lung Microbiome, Immunity, and the Pathogenesis of Chronic Lung Disease
O’Dwyer, D. N., Dickson, R. P., & Moore, B. B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600279 · Cited by 362 · cited 1×
“For instance, the lungs’ surface approximates 1 m(2) per kg of body weight and is not sterile (108).”
BackgroundLee, S. H., Sung, J. Y., Yong, D., Chun, J., Kim, S. Y., Song, J. H., Chung, K. S., Kim, E. Y., Jung, J. Y., Kang, Y. A., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.10.016 · Cited by 354
Suzuki, M., Mimuro, H., Kiga, K., Fukumatsu, M., Ishijima, N., Morikawa, H., Nagai, S., Koyasu, S., Gilman, R. H., Kersulyte, D., et al. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2008.11.010 · Cited by 338
Talimogene laherparepvec: First in class oncolytic virotherapy
Conry, R. M., Westbrook, B., McKee, S., & Norwood, T. G. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1412896 · Cited by 335
Does the cell number 109still really fit one gram of tumor tissue?
Del Monte, U. (2009) · Cell Cycle · doi:10.4161/cc.8.3.7608 · Cited by 330
Lower Airway Dysbiosis Affects Lung Cancer Progression
Tsay, J.-C. J., Wu, B. G., Sulaiman, I., Gershner, K., Schluger, R., Li, Y., Yie, T.-A., Meyn, P., Olsen, E., Perez, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0263 · Cited by 322 · cited 4×
“The clinical importance of this observation has been recently brought up in 83 lung cancer patients (25).”
BackgroundInfluentialUribe-Herranz, M., Rafail, S., Beghi, S., Gil-de-Gómez, L., Verginadis, I., Bittinger, K., Pustylnikov, S., Pierini, S., Perales-Linares, R., Blair, I. A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124332 · Cited by 316 · cited 1×
“Radiotherapy of tumor lesions was more effective when vancomycin eliminated Clostridiales-derived immunosuppressivemetabolites (butyrate and propionate) putatively by increasing DC antigen presentation and concomitant CD8 T cell priming (72); conversely, gut microbial–derived propionate and tryptophan pathway metaboli…”
BackgroundYelin, I., Flett, K. B., Merakou, C., Mehrotra, P., Stam, J., Snesrud, E., Hinkle, M., Lesho, E., McGann, P., McAdam, A. J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0626-9 · Cited by 315 · cited 1×
“In critically ill patients, commercial probiotic use may even cause bacteremia (145).”
BackgroundSomatic mosaicism: implications for disease and transmission genetics
Campbell, I. M., Shaw, C. A., Stankiewicz, P., & Lupski, J. R. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.03.013 · Cited by 296
Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances
Zheng, M., Huang, J., Tong, A., & Yang, H. (2019) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2019.10.007 · Cited by 295
Dietary patterns and cancer risk
Steck, S. E., & Murphy, E. A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0227-4 · Cited by 292 · cited 1×
“Dietary effects on cancer were recently reviewed in detail, with many epidemiological associations but few causal mechanisms (138).”
BackgroundStarnes, C. O. (1992) · Nature · doi:10.1038/357011a0 · Cited by 284 · cited 2×
“Shortly thereafter, William Coley started testing a highly contentious and sometimes lethal vaccine of live or heat-killed Streptococcus and Serratia species on terminal cancer patients, which was only later shown to yield >10-year disease-free survival in ~30%of them (60 of 210 total), representing the first intentio…”
BackgroundAssociation Between Bacteremia From Specific Microbes and Subsequent Diagnosis of Colorectal Cancer
Kwong, T. N. Y., Wang, X., Nakatsu, G., Chow, T. C., Tipoe, T., Dai, R. Z. W., Tsoi, K. K. K., Wong, M. C. S., Tse, G., Chan, M. T. V., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.028 · Cited by 280 · cited 3×
“hematogenous spread (117, 172, 173) or colonized micrometastases (19) may”
BackgroundTopography of cancer-associated immune cells in human solid tumors
Kather, J. N., Suarez-Carmona, M., Charoentong, P., Weis, C.-A., Hirsch, D., Bankhead, P., Horning, M., Ferber, D., Kel, I., Herpel, E., et al. (2018) · eLife · doi:10.7554/elife.36967 · Cited by 280
Le Noci, V., Guglielmetti, S., Arioli, S., Camisaschi, C., Bianchi, F., Sommariva, M., Storti, C., Triulzi, T., Castelli, C., Balsari, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.090 · Cited by 270 · cited 7×
“(18, 19, 25, 46, 112), gut communication (15, 20, 23), hematogenous spread (172, 173), and intrametastatic”
BackgroundInfluentialAbed, J., Maalouf, N., Manson, A. L., Earl, A. M., Parhi, L., Emgård, J. E. M., Klutstein, M., Tayeb, S., Almogy, G., Atlan, K. A., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00400 · Cited by 267
Helicobacter and gastric MALT lymphoma
Stolte, M., Bayerdörffer, E., Morgner, A., Alpen, B., Wündisch, T., Thiede, C., & Neubauer, A. (2002) · Gut · doi:10.1136/gut.50.suppl_3.iii19 · Cited by 265
Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy
Gil-Cruz, C., Perez-Shibayama, C., De Martin, A., Ronchi, F., van der Borght, K., Niederer, R., Onder, L., Lütge, M., Novkovic, M., Nindl, V., et al. (2019) · Science · doi:10.1126/science.aav3487 · Cited by 260 · cited 1×
“thetaiotaomicron–derived b-galactosidase and host cardiac myosin heavy chain 6 could drive lethal autoimmune inflammatory cardiomyopathy (79); conversely, Nanjundappa and others reported how cross-reactivity between Bacteroides species–derived integrase and host islet-specific glucose-6-phosphatase catalytic subunit-r…”
BackgroundCOHEN, R. J., SHANNON, B. A., McNEAL, J. E., SHANNON, T., & GARRETT, K. L. (2005) · Journal of Urology · doi:10.1097/01.ju.0000158161.15277.78 · Cited by 246
Highly multiplexed spatial mapping of microbial communities
Shi, H., Shi, Q., Grodner, B., Lenz, J. S., Zipfel, W. R., Brito, I. L., & De Vlaminck, I. (2020) · Nature · doi:10.1038/s41586-020-2983-4 · Cited by 245
Hamada, T., Zhang, X., Mima, K., Bullman, S., Sukawa, Y., Nowak, J. A., Kosumi, K., Masugi, Y., Twombly, T. S., Cao, Y., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0174 · Cited by 232
Viruses and Human Cancers: a Long Road of Discovery of Molecular Paradigms
White, M. K., Pagano, J. S., & Khalili, K. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00124-13 · Cited by 228
Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice
Li, Y., Tinoco, R., Elmén, L., Segota, I., Xian, Y., Fujita, Y., Sahu, A., Zarecki, R., Marie, K., Feng, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09525-y · Cited by 212 · cited 13×
“Nonhematopoietic components of the intestinal mucosa are also linked to the TME (77).”
InfluentialRoberti, M. P., Yonekura, S., Duong, C. P. M., Picard, M., Ferrere, G., Tidjani Alou, M., Rauber, C., Iebba, V., Lehmann, C. H. K., Amon, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0882-8 · Cited by 208
Self-citationPrebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth
Li, Y., Elmén, L., Segota, I., Xian, Y., Tinoco, R., Feng, Y., Fujita, Y., Segura Muñoz, R. R., Schmaltz, R., Bradley, L. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.035 · Cited by 189 · cited 2×
“muciniphila by prebiotic mucin decreased growth kinetics of aggressive melanoma inagutmicrobiota– andT cell–dependent manner, reducing serum levels of proinflammatory and immunosuppressive IL-6, IL-1a, IL-10, IL-17A, and IL-23 cytokines (87); notably, prebiotic inulin operated through a different mode of action, facil…”
BackgroundLimeta, A., Ji, B., Levin, M., Gatto, F., & Nielsen, J. (2020) · JCI Insight · doi:10.1172/jci.insight.140940 · Cited by 185 · cited 1×
“Moreover, observations in humans and mice of gut microbes that stratify therapy response, particularly immunotherapy (16, 17, 21, 26), have not uncommonly shown varying taxonomic differences that persist despite uniform bioinformatic reanalyses, although there is greater concordance when examining functional profiles…”
BackgroundCommensal bacteria stimulate antitumor responses via T cell cross-reactivity
Bessell, C. A., Isser, A., Havel, J. J., Lee, S., Bell, D. R., Hickey, J. W., Chaisawangwong, W., Glick Bieler, J., Srivastava, R., Kuo, F., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.135597 · Cited by 184
A stabilized microbial ecosystem of self-limiting bacteria using synthetic quorum-regulated lysis
Scott, S. R., Din, M. O., Bittihn, P., Xiong, L., Tsimring, L. S., & Hasty, J. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.83 · Cited by 173
Self-citationThe microbiome and the hallmarks of cancer
Fulbright, L. E., Ellermann, M., & Arthur, J. C. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006480 · Cited by 164
Rock-paper-scissors: Engineered population dynamics increase genetic stability
Liao, M. J., Din, M. O., Tsimring, L., & Hasty, J. (2019) · Science · doi:10.1126/science.aaw0542 · Cited by 160
Self-citationMicrobiota-modulated CART + enteric neurons autonomously regulate blood glucose
Muller, P. A., Matheis, F., Schneeberger, M., Kerner, Z., Jové, V., & Mucida, D. (2020) · Science · doi:10.1126/science.abd6176 · Cited by 154 · cited 1×
“A subset of microbiota-responsive neurons could influence metabolic control independent of the central nervous system (98).”
BackgroundVijay-Kumar, M., Chassaing, B., Kumar, M., Baker, M., & Singh, V. (2014) · Biomedical Journal · doi:10.4103/2319-4170.130922 · Cited by 153
Quorum-sensing Salmonella selectively trigger protein expression within tumors
Swofford, C. A., Van Dessel, N., & Forbes, N. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414558112 · Cited by 145
Insights from 100 years of research with probiotic E. coli
Wassenaar, T. M. (2016) · European Journal of Microbiology and Immunology · doi:10.1556/1886.2016.00029 · Cited by 145
Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions
Kramer, M. G., Masner, M., Ferreira, F. A., & Hoffman, R. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00016 · Cited by 145
Microbiota and cancer immunotherapy: in search of microbial signals
Gharaibeh, R. Z., & Jobin, C. (2019) · Gut · doi:10.1136/gutjnl-2018-317220 · Cited by 144
Staffas, A., Burgos da Silva, M., Slingerland, A. E., Lazrak, A., Bare, C. J., Holman, C. D., Docampo, M. D., Shono, Y., Durham, B., Pickard, A. J., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.03.002 · Cited by 143
Fischer, J. C., Bscheider, M., Eisenkolb, G., Lin, C.-C., Wintges, A., Otten, V., Lindemans, C. A., Heidegger, S., Rudelius, M., Monette, S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2513 · Cited by 142
Wnt/β-Catenin Signaling as a Molecular Target by Pathogenic Bacteria
Silva-García, O., Valdez-Alarcón, J. J., & Baizabal-Aguirre, V. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02135 · Cited by 142
Microbial guardians of skin health
Stacy, A., & Belkaid, Y. (2019) · Science · doi:10.1126/science.aat4326 · Cited by 140
Gastrointestinal tract modeling using organoids engineered with cellular and microbiota niches
Min, S., Kim, S., & Cho, S.-W. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0386-0 · Cited by 139
Design and application of oncolytic viruses for cancer immunotherapy
Ylösmäki, E., & Cerullo, V. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.11.016 · Cited by 136
Fecal microbiome signatures of pancreatic cancer patients
Half, E., Keren, N., Reshef, L., Dorfman, T., Lachter, I., Kluger, Y., Reshef, N., Knobler, H., Maor, Y., Stein, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53041-4 · Cited by 133
Huang, X.-Z., Gao, P., Song, Y.-X., Xu, Y., Sun, J.-X., Chen, X.-W., Zhao, J.-H., & Wang, Z.-N. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1665973 · Cited by 132
Daisley, B. A., Chanyi, R. M., Abdur-Rashid, K., Al, K. F., Gibbons, S., Chmiel, J. A., Wilcox, H., Reid, G., Anderson, A., Dewar, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18649-5 · Cited by 128
T cell receptor cross-reactivity between gliadin and bacterial peptides in celiac disease
Petersen, J., Ciacchi, L., Tran, M. T., Loh, K. L., Kooy–Winkelaar, Y., Croft, N. P., Hardy, M. Y., Chen, Z., McCluskey, J., Anderson, R. P., et al. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0353-4 · Cited by 127
A Gut Microbial Mimic that Hijacks Diabetogenic Autoreactivity to Suppress Colitis
Nanjundappa, R. H., Ronchi, F., Wang, J., Clemente‐Casares, X., Yamanouchi, J., Umeshappa, C. S., Yang, Y., Blanco, J., Bassolas-Molina, H., Salas, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.022 · Cited by 122
Arthur, J. C., Gharaibeh, R. Z., Uronis, J. M., Perez-Chanona, E., Sha, W., Tomkovich, S., Mühlbauer, M., Fodor, A. A., & Jobin, C. (2013) · Scientific Reports · doi:10.1038/srep02868 · Cited by 118 · cited 1×
“tested for impacts on antitumor and systemic immunity, with certain formulations actually increasing tumorigenesis (144).”
BackgroundPotential Pharmaceutical and Food Applications of Postbiotics: A Review
Rad, A. H., Abbasi, A., Kafil, H. S., & Ganbarov, K. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666200516154833 · Cited by 113
So, K. A., Yang, E. J., Kim, N. R., Hong, S. R., Lee, J.-H., Hwang, C.-S., Shim, S.-H., Lee, S. J., & Kim, T. J. (2020) · PLOS ONE · doi:10.1371/journal.pone.0238705 · Cited by 113 · cited 2×
“(18, 19, 25, 46, 112), gut communication (15, 20, 23), hematogenous spread (172, 173), and intrametastatic”
BackgroundMutagenesis by Microbe: the Role of the Microbiota in Shaping the Cancer Genome
Barrett, M., Hand, C. K., Shanahan, F., Murphy, T., & O’Toole, P. W. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.01.019 · Cited by 108 · cited 1×
“fragilis–derived toxin (22, 37, 38, 40, 41); (ii) CagA-mediated or IL-17– producing gd T cell–mediated inflammation in stomach and lung cancers, respectively (18, 103); (iii) chemoresistance through direct microbial metabolism (cytidine deaminase degradation of gemcitabine) in pancreatic cancer or indirect amplificati…”
BackgroundAn intact gut microbiome protects genetically predisposed mice against leukemia
Vicente-Dueñas, C., Janssen, S., Oldenburg, M., Auer, F., González-Herrero, I., Casado-García, A., Isidro-Hernández, M., Raboso-Gallego, J., Westhoff, P., Pandyra, A. A., et al. (2020) · Blood · doi:10.1182/blood.2019004381 · Cited by 106 · cited 2×
“However, an intact gut microbiome was later shown to be necessary to prevent leukemia progression in genetically predisposed mice (92).”
Background(1882) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0029-1196806 · Cited by 96
Boot, A., Ng, A. W. T., Chong, F. T., Ho, S.-C., Yu, W., Tan, D. S. W., Iyer, N. G., & Rozen, S. G. (2020) · Genome Research · doi:10.1101/gr.255620.119 · Cited by 58
Engineering microbial systems to explore ecological and evolutionary dynamics
Tanouchi, Y., Smith, R. P., & You, L. (2012) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2012.01.006 · Cited by 56
Quantitative Bacterial Tissue Cultures From 209 Prostatectomy Specimens: Findings and Implications
Gorelick, J. I., Senterfit, L. B., & Vaughan, E. D. (1988) · Journal of Urology · doi:10.1016/s0022-5347(17)42292-0 · Cited by 54
Liu, J., Luo, M., Zhang, Y., Cao, G., & Wang, S. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-5832 · Cited by 41 · cited 1×
“Similarly, cervical cancer caused by persistent high-risk human papillomavirus infection is often associated with a deviated cervical microflora (111, 112).”
BackgroundNon-Melanoma Skin Cancer: news from microbiota research
Squarzanti, D. F., Zavattaro, E., Pizzimenti, S., Amoruso, A., Savoia, P., & Azzimonti, B. (2020) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2020.1794792 · Cited by 40
Liu, W., Qiu, C., Wu, S., Xia, X., Wu, A., Cui, F., Gu, Y., Zhang, X., & Cao, J. (2015) · Journal of Radiation Research · doi:10.1093/jrr/rru100 · Cited by 29
CANTWELL, A. R., & KELSO, D. W. (1981) · The Journal of Dermatologic Surgery and Oncology · doi:10.1111/j.1524-4725.1981.tb00682.x · Cited by 25
Michelis, F. V., Messner, H. A., Loach, D., Uhm, J., Gupta, V. K., Lipton, J. H., Seftel, M. D., Kuruvilla, J. G., & Kim, D. D. H. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12338 · Cited by 23
Brook, I., & Ledney, G. D. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.1.63 · Cited by 23
(1990) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.40.2.103 · Cited by 21
Lowy, D. R., & Schiller, J. T. (2017) · JAMA · doi:10.1001/jama.2017.11706 · Cited by 11
Research works printed but not linked: 2
- W. Busch, Aus der Sitzung der medicinischen Section vom 13 November 1867. Berl Klin Wochenschr 5, 137 (1868).
- T. J. Glover, The bacteriology of cancer. Canada Lancet Pract. 75, 92–111 (1930).
Cited by
The role of ROS in tumour development and progression
Cheung, E. C., & Vousden, K. H. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00435-0 · Cited by 1,595
Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer
Galeano Niño, J. L., Wu, H., LaCourse, K. D., Kempchinsky, A. G., Baryiames, A., Barber, B., Futran, N., Houlton, J., Sather, C., Sicinska, E., et al. (2022) · Nature · doi:10.1038/s41586-022-05435-0 · Cited by 887
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment
Lam, K. C., Araya, R. E., Huang, A., Chen, Q., Di Modica, M., Rodrigues, R. R., Lopès, A., Johnson, S. B., Schwarz, B., Bohrnsen, E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.019 · Cited by 604
Self-citationCullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.006 · Cited by 578
Self-citation
Metadata
- Authors
- Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R.
- Affiliations
- Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA.
- Université Paris-Sud (FR)
- Weizmann Institute of Science (IL)
- University of California San Diego (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Knight, Rob
- ORCID
- Venue
- Science
- Published
- 2021-03-26
- Volume
- 371
- Issue
- 6536
- Pages
- 91-97
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8767999
- OpenAlex
- W3138215020
- Cited by
- 1,332
- References
- 176
- Citations by year
- 2026: 231 · 2025: 310 · 2024: 294 · 2023: 274 · 2022: 161 · 2021: 62
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-09-26)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (F30 CA243480, R01CA255206)
- RHU Torino Lumière (ANR-16-RHUS-0008)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- microbiome, cancer, gut microbiota, antitumor immunity, microbial metabolites, Toll-like receptors, immune checkpoint inhibitors, intratumoral bacteria, bacteriophages, gastrointestinal cancer, cancer immunotherapy, microbiota modulation, engineered bacteria, Rous sarcoma virus, viral oncogenesis, molecular mimicry
- MeSH terms
- Gastrointestinal Microbiome, Host Microbial Interactions, Anti-Bacterial Agents, Antineoplastic Agents, Bacteria, Genetic Engineering, Humans, Immunotherapy, Lymphoid Tissue, Neoplasms, Virus Physiological Phenomena, Bacterial Physiological Phenomena, Oncolytic Virotherapy, Adaptive Immunity, Immunomodulation, Tumor Microenvironment, Carcinogenesis, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.